Nanjing, China
Bioantibody is a biotechnology startup based in China, founded in 2019. With the slogan "Biotech For A Better Life," the company is dedicated to improving global ecology through science and technology. Its diverse product pipelines, spanning across cardiovascular and cerebrovascular, inflammation, infectious diseases, tumors, hormones, and other categories, have garnered significant trust from customers. Notably, its COVID-19 series of products has reached over 60 countries worldwide, underlining its global outreach and impact.
The recent milestone for Bioantibody was the CNY100.00M Series A investment led by Bondshine Capital, Guoqian Venture Capital, 梧桐树资本, Fang Fund Partners, New Industry Ventures, on 12 January 2023. This significant investment reflects the confidence of prominent investors in the company's potential to revolutionize the health care and pharmaceutical industries with its innovative solutions. With its steadfast commitment to innovation and customer-centric approach, Bioantibody is poised to make a remarkable contribution to human ecology and health.
